Please try another search
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform, it is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC410, NC762 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein (B7-H4) a protein expressed on multiple tumor types. NC525 (LAIR-1 mAb) is a LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells (LSCs).
Name | Age | Since | Title |
---|---|---|---|
Michael S. Richman | 61 | 2015 | Co-Founder, CEO, President & Director |
Mario Sznol | 64 | - | Member of Scientific Advisory Board |
Stephen D. Miller | - | - | Member of Scientific Advisory Board |
Stephen W. Webster | 61 | 2019 | Independent Director |
David S. Kabakoff | 74 | 2015 | Independent Chairman of the Board |
Elaine V. Jones | 67 | 2015 | Independent Director |
Lieping Chen | 64 | 2015 | Co-Founder & Chairman of Scientific Advisory Board |
Chau Quang Khuong | 46 | 2015 | Independent Director |
John G. Houston | 63 | 2020 | Independent Director |
Anne Elizabeth Borgman-Hagey | 55 | 2021 | Independent Director |
Weiping Zou | - | 2021 | Member of Scientific Advisory Board |
Ellen Gwen Feigal | 69 | 2021 | Independent Director |
Brahm Segal | - | 2022 | Member of Scientific Advisory Board |
Lisa M. Coussens | - | 2022 | Member of Scientific Advisory Board |
Ursula A. Matulonis | - | 2021 | Member of Scientific Advisory Board |
Rakesh Dixit | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review